Bionano Genomics, Inc. (NASDAQ:BNGO) Sees Significant Increase in Short Interest

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 706,400 shares, an increase of 113.2% from the August 31st total of 331,300 shares. Based on an average daily volume of 499,300 shares, the days-to-cover ratio is currently 1.4 days. Approximately 9.8% of the company’s stock are sold short. Approximately 9.8% of the company’s stock are sold short. Based on an average daily volume of 499,300 shares, the days-to-cover ratio is currently 1.4 days.

Bionano Genomics Stock Up 1.6%

Shares of NASDAQ:BNGO opened at $1.92 on Monday. The company’s fifty day moving average is $3.03 and its 200-day moving average is $3.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.41 and a current ratio of 1.76. Bionano Genomics has a 52 week low of $1.50 and a 52 week high of $28.14. The company has a market capitalization of $7.95 million, a PE ratio of -0.01 and a beta of 2.19.

Bionano Genomics (NASDAQ:BNGO) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.69) by $0.70. The firm had revenue of $6.73 million during the quarter, compared to the consensus estimate of $6.90 million. Bionano Genomics had a negative net margin of 271.02% and a negative return on equity of 129.41%. Bionano Genomics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $11.00 price target (up previously from $10.00) on shares of Bionano Genomics in a research note on Monday, August 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bionano Genomics in a research note on Saturday, September 27th. Finally, Wall Street Zen raised Bionano Genomics from a “sell” rating to a “hold” rating in a research report on Monday, August 25th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

Hedge Funds Weigh In On Bionano Genomics

An institutional investor recently bought a new position in Bionano Genomics stock. Everstar Asset Management LLC bought a new position in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 44,984 shares of the company’s stock, valued at approximately $126,000. Everstar Asset Management LLC owned about 1.45% of Bionano Genomics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.